- Home
- APLS vs RARE Comparison
APLS vs RARE Comparison
Compare APLS & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLS
- RARE
- Stock Information
- Founded
- APLS 2009
- RARE 2010
- Country
- APLS United States
- RARE United States
- Employees
- APLS N/A
- RARE N/A
- Industry
- APLS Biotechnology: Pharmaceutical Preparations
- RARE Biotechnology: Pharmaceutical Preparations
- Sector
- APLS Health Care
- RARE Health Care
- Exchange
- APLS Nasdaq
- RARE Nasdaq
- Market Cap
- APLS 4.4B
- RARE 5.2B
- IPO Year
- APLS 2017
- RARE 2014
- Fundamental
- Price
- APLS $27.75
- RARE $46.02
- Analyst Decision
- APLS Buy
- RARE Strong Buy
- Analyst Count
- APLS 19
- RARE 14
- Target Price
- APLS $49.89
- RARE $86.79
- AVG Volume (30 Days)
- APLS 4.0M
- RARE 974.4K
- Earning Date
- APLS 11-05-2024
- RARE 11-05-2024
- Dividend Yield
- APLS N/A
- RARE N/A
- EPS Growth
- APLS N/A
- RARE N/A
- EPS
- APLS N/A
- RARE N/A
- Revenue
- APLS $715,216,000.00
- RARE $522,745,000.00
- Revenue This Year
- APLS $95.59
- RARE $27.29
- Revenue Next Year
- APLS $13.77
- RARE $18.30
- P/E Ratio
- APLS N/A
- RARE N/A
- Revenue Growth
- APLS 162.10
- RARE 27.44
- 52 Week Low
- APLS $24.34
- RARE $37.02
- 52 Week High
- APLS $73.80
- RARE $60.37
- Technical
- Relative Strength Index (RSI)
- APLS 47.09
- RARE 34.61
- Support Level
- APLS $25.76
- RARE $43.04
- Resistance Level
- APLS $30.80
- RARE $53.04
- Average True Range (ATR)
- APLS 1.84
- RARE 2.14
- MACD
- APLS 0.04
- RARE -0.35
- Stochastic Oscillator
- APLS 52.79
- RARE 28.57
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.